Vermillion
Aspira Q2 Revenues More Than Double
The company reported total revenues of $1.8 million, up from $746,000 a year ago, and posted sales of 4,553 OVA1plus tests, up from 2,458 in Q2 2020.
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.
Aspira Women's Health Q1 Revenues Up 25 Percent
The company's Q1 revenues rose to $1.5 million from $1.2 million as it performed 3,775 OVA1 tests, up 3 percent from 3,654 tests in Q1 2020.
Aspira Prices $45M Offering of Common Stock
The company, formerly called Vermillion, plans to offer 6 million shares of its common stock at $7.50 per share.
In Brief This Week: BioReference Laboratories, PerkinElmer, Fluidigm, Invitae, and More
News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.
Nov 12, 2020
Aspira Q3 Revenues Down 8 Percent
Aug 13, 2020
Aspira Q2 Revenues Down 32 Percent
Jul 1, 2020
Aspira Eyes $11M in Private Equity Financing
May 14, 2020
Vermillion Q1 Revenues Up 55 Percent
Mar 26, 2020
Vermillion Q4 Revenues Up 42 Percent
Nov 13, 2019
Nov 12, 2019
Vermillion Q3 Revenues Up 66 Percent
Aug 8, 2019
Vermillion Q2 Revenues Up 61 Percent
Jun 26, 2019
Vermillion Eyes $17M in Public Offering of Stock
May 14, 2019
Vermillion Q1 Revenues Up 24 Percent
Mar 28, 2019
Vermillion Q4 Revenues Up 16 Percent
Jan 15, 2019
Cigna Covering Vermillion's OVA1 Ovarian Cancer Test
Dec 13, 2018
Nov 8, 2018